CDC: Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12–18 Years

The Centers for Disease Control and Prevention (CDC) have released a report about the effectiveness of Pfizer-BioNTech mRNA vaccination against COVID-19 hospitalization among persons aged 12–18 years.

The findings in the report suggested that among hospitalized U.S. patients aged 12–18 years, vaccine effectiveness of 2 doses of Pfizer-BioNTech vaccine against COVID-19 hospitalization during June–September 2021, was 93% (95% confidence interval = 83%–97%).

Key evaluation from the report demonstrated that 2 doses of Pfizer-BioNTech vaccine were highly effective in preventing COVID-19 hospitalization among persons aged 12–18 years, reinforcing the importance of vaccination to protect U.S. youths against severe COVID-19.

To read the report in full, please click on the link below.
CDC: Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12–18 Years


Save the date for our virtual Clinical Vaccinology Update (CVU)!

MVEC are pleased to announce we will be hosting a virtual Clinical Vaccinology Update (CVU) on Thursday 18 and Friday 19 November, 2021.

Program details and ticketing information will be announced shortly via our MVEC Events Page.


New resource: The MVEC Conversation: myocarditis/pericarditis following mRNA vaccines​

Following on from our CVU mini virtual event: Matters of the heart: myocarditis and pericarditis associated with COVID-19 mRNA vaccination, The Melbourne Vaccine Education Centre is excited to announce our latest resource The MVEC Conversation: myocarditis/pericarditis following mRNA vaccines​. 

This vodcast takes a deeper look into this adverse event of special interest (AESI) and features special guest Dr. Tom Shimabukuro, the deputy director of the Immunization Safety Office at the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia, in conversation with Dr Daryl Cheng and Associate Professor Nigel Crawford.

To find out more about this resource, please visit our MVEC Events page.


Commonwealth-funded places available for Nurse Immuniser course

There are limited places available for Registered Nurses (RNs) with one year of clinical experience to complete the Commonwealth-funded Nurse Immuniser short course free of charge (conditions apply).

The immunisation (Nurse immuniser) short course is based on the  National Immunisation Education Framework for Health Professionals (2017) and has been accredited by the National body for health education Health Education Services Australia (HESA).

To find out more information on this course, please click on the links below. Please note some allocations have been exhausted.
The University of Melbourne: The immunisation (Nurse immuniser) short course
Benchmarque Group Immunisation Endorsement Pathway


A recording of the 30th August CVU mini is now available

Thank you to all who attended our recent CVU miniseries event Matters of the heart: Myocarditis and pericarditis associated with COVID-19 mRNA vaccination on 30th August 2021.

This interactive webinar took an in-depth look at an important vaccine safety signal associated with COVID-19 mRNA vaccines (Pfizer and Moderna).

A recording of this event is now available via our education portal.

To access this recording please follow the link below:

CVU mini - 30th August 2021


MVEC animation: Myocarditis, pericarditis and COVID-19 vaccines

MVEC have created a new animation to help explain myocarditis and pericarditis which have been reported in a small number of individuals who have received mRNA COVID-19 vaccines Comirnaty™ and Moderna.

To view the animation and to find out more information, please refer to our myocarditis, pericarditis following COVID-19 mRNA vaccines immunisation reference page:
MVEC animation: Myocarditis and pericarditis following COVID-19 mRNA vaccines


Federal Government Announces No Fault COVID-19 Indemnity Scheme

Federal Health Minister Greg Hunt has announced the details of the no fault COVID-19 Vaccine Claim Scheme following extensive consultation with the peak medical, healthcare, business and insurance sectors to ensure a comprehensive National Scheme.

The purpose of the Scheme will be to provide Australians with quick access to compensation for COVID-19 claims related to the administration of a Therapeutic Goods Administration approved COVID-19 vaccine delivered through a Commonwealth Government approved program.

From 6 September Australians who suffer injury and loss of income due to their COVID-19 vaccine will be able to register their intent to claim from the COVID-19 vaccine claims scheme webpage.

To read more, follow the link below:
Federal Government Announcement: No Fault COVID-19 Indemnity Scheme


FDA news release: FDA Approves First COVID-19 Vaccine

The US Food and Drug Administration (FDA) has granted full approval of Pfizer-BioNTech COVID-19 vaccine for individuals 16 years of age and above. The mRNA vaccine was first approved under emergency use authorisation back in December 2020, and is currently the first and only COVID-19 vaccine to receive full authorisation for use.

Pfizer CEO Albert Bourla said in a statement the FDA's approval "affirms the efficacy and safety profile of our vaccine at a time when it is urgently needed."

All FDA-approved vaccines undergo a rigorous standard process for reviewing the quality, safety, and effectiveness. For Comirnaty, new clinical data is used in conjunction with existing information submitted during the initial EUA stage. The FDA’s approval process concluded that the vaccine was 91% effective in preventing COVID-19 disease based on the evaluation of approximately 20,000 vaccine recipients as well as 20,000 placebo recipients aged 16 years and above. Furthermore, to better assess the long term safety outcomes, approximately 12,000 recipients were monitored for an additional 6 months following their second dose of the vaccine. Conclusively, results suggest that the vaccines show an increased risk of myocarditis and pericarditis, particularly among males under the age of 40, following their second jab. The FDA and Centers for Disease Control and Prevention along with the company will continue to monitor the safety and effectiveness of the Comirnaty vaccines, to ensure any concerns continue to be identified and evaluated in a timely manner.

To read the full article, click on the link below:
https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine


CVU mini event 30th August 2021 - Reminder to register

A reminder to register for our next Clinical Vaccinology Update (CVU) mini event: Matters of the heart: Myocarditis and pericarditis associated with COVID-19 mRNA vaccination on Monday 30th August 2021, at 7pm AEST.

To view the full program and to register for this event, please visit our Events page.

A recording of Matters of the heart: Myocarditis and pericarditis associated with COVID-19 mRNA vaccination will be available on our Education Portal following the event.


Healthed lecture series featuring Associate Professor Nigel Crawford

MVEC’s Associate Professor Nigel Crawford delivered the COVID-19 Update as part of the recent Healthed Australia online lecture series.

In this lecture, A/Prof Nigel Crawford discussed the following:

  • The role of ATAGI and its relevance to the current pandemic
  • Overview of the newly available Moderna vaccination
  • Rationale and evidence behind the upcoming push for vaccinating children 12 yrs of age and older
  • Update on the clinical features and management pathways for Pfizer-related myocarditis, pericarditis
  • AZ-related clots
  • Lessons learnt from other countries dealing with the Delta pandemic

To listen to the lecture in full, click on the link below:
Healthed lecture series 18th August: COVID Update


About MVEC

The Melbourne Vaccine Education Centre (MVEC) is an educational website, developed with the aim of providing up-to-date immunisation information for both healthcare professionals and members of the public. We are based at Murdoch Children’s Research Institute (MCRI), a research organisation, and are affiliated with SAEFVIC (Surveillance of Adverse Events Following Vaccination in the Community), the Victorian Vaccine Safety Service.